SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a hot topic after receiving FDA Fast Track designation for sonelokimab in a rare inflammatory disorder, driving strong community conviction that its highly-anticipated investor day will underscore significant undervaluation and reignite acquisition speculation.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

Starfighters Space is trending as its IPO quiet period concludes and investors await potential news regarding an FAA Space Launch license, fueling community debate over its tiny float and high short interest, particularly amidst broader speculation for the upcoming Space X IPO.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending following a challenging Q4 earnings report that revealed declining U.S. sales and a weak 2026 outlook, leading to analyst downgrades and high short interest. Community discussion is split between concerns over the company's debt, potential dividend cuts, and ongoing CEO search versus optimism for a turnaround, short squeeze, or potential buyout at its current low valuation.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera (ATOM) is trending due to recent earnings call comments from its CEO, fueling speculation that its Mears Silicon Technology (MST) is making significant progress with major chipmakers for Gate-All-Around and DRAM, alongside breakthroughs in GaN-on-Silicon for AI and data centers. The community is actively debating whether record trading volumes and increased management accountability signal a long-awaited valuation reset for the pre-revenue semiconductor innovator.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as its AXPAXLI drug successfully met the primary endpoint in the SOL-1 Phase 3 trial for wet AMD, demonstrating superiority over Eylea and offering a reduced treatment burden. Despite these positive results, the stock saw a significant sell-off driven by market concerns over the efficacy margin and control arm performance, sparking widespread debate among investors whether the reaction is an overcorrection or a fundamental reassessment.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion (INFQ) is highly active after its recent NYSE debut following a SPAC merger, with the community bullish on its neutral atom quantum technology and significant partnerships with entities like NASA and NVIDIA, positioning it as a leading contender against other quantum sector peers.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is experiencing intense debate following impressive Q2 earnings and strong guidance, attributed to surging demand for its optical components in AI data centers. Bulls are celebrating its significant run as a critical AI infrastructure play, while bears vigorously argue it's extremely overvalued and due for a sharp correction.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is trending following robust Phase 2 data for its NXC-201 CAR-T therapy in AL Amyloidosis, prompting an upsized institutional offering and fueling community discussions of a potential buyout or short squeeze. The therapy's strong efficacy and safety profile, alongside its broader potential in autoimmune conditions, positions it as a significant long-term value play.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is actively discussed ahead of its earnings report, with community sentiment split between concerns that AI could disrupt cybersecurity and the belief that AI-powered solutions, like those from its significant Google Cloud partnership and recent acquisitions, will drive increased demand in the sector.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Holdings Inc

Ondas Holdings is trending amidst a series of new contracts for its autonomous drone and counter-UAS systems in Europe and for defense applications. This influx of positive news is driving community chatter about a potential short squeeze and the company's growing significance as a "Mini-Anduril" in the expanding defense technology sector, even as overall market conditions remain volatile.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Earnings Preview: Cytokinetics (CYTK) Q4 Earnings Expected to Decline

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?

BMYs 2025 results highlight a shifting revenue mix as 17% growth in newer drugs offsets legacy declines, with more erosion expected in 2026.

Cytokinetics (CYTK) Expected to Announce Earnings on Tuesday

Cytokinetics (NASDAQ:CYTK) will be releasing its Q4 2025 earnings after the market closes on Tuesday, February 24. (View Earnings Report at...

Bayer's Asundexian Shows 26% Stroke Reduction in Late-Stage Study

Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for regulatory approval.

Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 15,000 Shares

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 15,000 shares of the stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of...

Andrew Callos Sells 15,000 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 15,000 shares of the firm's stock in a transaction dated Thursday, February 5th. The shares were sold at an average...

Truist Financial Forecasts Strong Price Appreciation for Cytokinetics (NASDAQ:CYTK) Stock

Truist Financial increased their target price on shares of Cytokinetics from $84.00 to $92.00 and gave the stock a "buy" rating in a report on Tuesday...

Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells 886 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 886 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $62.10...

Lisanti Capital Growth LLC Acquires New Position in Cytokinetics, Incorporated $CYTK

Lisanti Capital Growth LLC acquired a new stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with...

Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates

Regeneron (REGN) delivered earnings and revenue surprises of +8.32% and +1.77%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Cytokinetics Inc

Fundamental

Technical

A mix of both

Some investors focus on company fundamentals like earnings, growth, and valuation. Others rely on price action, trends, and momentum. Many use a combination of both to guide their decisions. What do you use?

What type of analysis drives your investment decisions?

CYTK
Cytokinetics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CYTK News

CYTKCytokinetics Inc